Comprehensive Stock Comparison
Compare Cellebrite DI Ltd. (CLBT) vs MongoDB, Inc. (MDB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | MDB | 19.2% revenue growth vs CLBT's 18.6% |
| Value | CLBT | Lower P/E (36.3x vs 68.2x) |
| Quality / Margins | CLBT | 16.5% net margin vs MDB's -3.1% |
| Stability / Safety | CLBT | Beta 0.83 vs MDB's 1.68 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MDB | +22.8% vs CLBT's -28.1% |
| Efficiency (ROA) | CLBT | 8.3% ROA vs MDB's -2.0%, ROIC 18.5% vs -8.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Cellebrite provides digital intelligence solutions for legally sanctioned investigations by law enforcement and government agencies. It generates revenue primarily from software licenses and maintenance fees for its forensic data extraction and analysis platforms — including its Universal Forensic Extraction Device and DI platform — which help investigators access and analyze digital evidence from locked, encrypted, or deleted sources. The company's key advantage is its deep technical expertise in overcoming device security barriers and its established relationships with government agencies worldwide, creating high switching costs in a specialized, regulated market.
MongoDB is a modern database platform company that offers a flexible, document-based database system as an alternative to traditional relational databases. It generates revenue primarily through its cloud-based MongoDB Atlas service — which accounts for over 60% of total revenue — along with its on-premise Enterprise Advanced licenses and professional services. The company's key advantage is its developer-friendly document model that enables faster application development and its first-mover position in the NoSQL database market.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CLBT leads in 3 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 2 categories are tied.
Financial Metrics (TTM)
MDB is the larger business by revenue, generating $2.3B annually — 4.9x CLBT's $476M. CLBT is the more profitable business, keeping 16.5% of every revenue dollar as net income compared to MDB's -3.1%.
| Metric | CLBTCellebrite DI Ltd. | MDBMongoDB, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $476M | $2.3B |
| EBITDAEarnings before interest/tax | $78M | -$121M |
| Net IncomeAfter-tax profit | $78M | -$71M |
| Free Cash FlowCash after capex | $160M | $355M |
| Gross MarginGross profit ÷ Revenue | +84.2% | +71.6% |
| Operating MarginEBIT ÷ Revenue | +14.0% | -6.7% |
| Net MarginNet income ÷ Revenue | +16.5% | -3.1% |
| FCF MarginFCF ÷ Revenue | +33.7% | +15.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | +18.1% | +18.7% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.7% | +81.0% |
Valuation Metrics
| Metric | CLBTCellebrite DI Ltd. | MDBMongoDB, Inc. |
|---|---|---|
| Market CapShares × price | $3.3B | $26.7B |
| Enterprise ValueMkt cap + debt − cash | $3.2B | $26.3B |
| Trailing P/EPrice ÷ TTM EPS | 43.03x | -189.87x |
| Forward P/EPrice ÷ next-FY EPS est. | 36.25x | 68.24x |
| PEG RatioP/E ÷ EPS growth rate | 0.73x | — |
| EV / EBITDAEnterprise value multiple | 40.33x | — |
| Price / SalesMarket cap ÷ Revenue | 6.86x | 13.32x |
| Price / BookPrice ÷ Book value/share | 6.88x | 8.80x |
| Price / FCFMarket cap ÷ FCF | 20.34x | 221.51x |
Profitability & Efficiency
CLBT delivers a 16.2% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-2 for MDB. MDB carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CLBT's 0.05x. On the Piotroski fundamental quality scale (0–9), MDB scores 5/9 vs CLBT's 4/9, reflecting solid financial health.
| Metric | CLBTCellebrite DI Ltd. | MDBMongoDB, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | +16.2% | -2.5% |
| ROA (TTM)Return on assets | +8.3% | -2.0% |
| ROICReturn on invested capital | +18.5% | -8.6% |
| ROCEReturn on capital employed | +13.8% | -8.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.05x | 0.01x |
| Net DebtTotal debt minus cash | -$102M | -$454M |
| Cash & Equiv.Liquid assets | $124M | $490M |
| Total DebtShort + long-term debt | $23M | $37M |
| Interest CoverageEBIT ÷ Interest expense | — | -9.95x |
Total Returns (with DRIP)
A $10,000 investment in CLBT five years ago would be worth $12,549 today (with dividends reinvested), compared to $8,315 for MDB. Over the past 12 months, MDB leads with a +22.8% total return vs CLBT's -28.1%. The 3-year compound annual growth rate (CAGR) favors CLBT at 29.4% vs MDB's 16.2% — a key indicator of consistent wealth creation.
| Metric | CLBTCellebrite DI Ltd. | MDBMongoDB, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -25.2% | -17.8% |
| 1-Year ReturnPast 12 months | -28.1% | +22.8% |
| 3-Year ReturnCumulative with dividends | +116.9% | +56.8% |
| 5-Year ReturnCumulative with dividends | +25.5% | -16.9% |
| 10-Year ReturnCumulative with dividends | +38.1% | +924.2% |
| CAGR (3Y)Annualised 3-year return | +29.4% | +16.2% |
Risk & Volatility
CLBT is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than MDB's 1.68 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MDB currently trades 73.9% from its 52-week high vs CLBT's 64.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CLBTCellebrite DI Ltd. | MDBMongoDB, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.83x | 1.68x |
| 52-Week HighHighest price in past year | $20.86 | $444.72 |
| 52-Week LowLowest price in past year | $11.76 | $140.78 |
| % of 52W HighCurrent price vs 52-week peak | +64.0% | +73.9% |
| RSI (14)Momentum oscillator 0–100 | 43.9 | 43.7 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 1.2M |
Analyst Outlook
Wall Street rates CLBT as "Buy" and MDB as "Buy". Consensus price targets imply 54.9% upside for CLBT (target: $21) vs 33.1% for MDB (target: $437).
| Metric | CLBTCellebrite DI Ltd. | MDBMongoDB, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $20.67 | $437.20 |
| # AnalystsCovering analysts | 8 | 44 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 20 | Feb 26 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | 100 | 154.24 | +54.2% |
| MongoDB, Inc. (MDB) | 100 | 135.37 | +35.4% |
Cellebrite DI Ltd. (CLBT) returned +25% over 5 years vs MongoDB, Inc. (MDB)'s -17%. A $10,000 investment in CLBT 5 years ago would be worth $12,549 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | $172M | $476M | +176.8% |
| MongoDB, Inc. (MDB) | $65M | $2.0B | +2974.0% |
MongoDB, Inc.'s revenue grew from $65M (2016) to $2.0B (2025) — a 46.3% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | -1.1% | 16.5% | +1608.5% |
| MongoDB, Inc. (MDB) | -112.6% | -6.4% | +94.3% |
MongoDB, Inc.'s net margin went from -113% (2016) to -6% (2025).
Chart 4P/E Ratio History — 4 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | 340.8 | 58.2 | -82.9% |
Cellebrite DI Ltd. has traded in a 7x–341x P/E range over 4 years; current trailing P/E is ~43x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Cellebrite DI Ltd. (CLBT) | -0.01 | 0.31 | +3200.0% |
| MongoDB, Inc. (MDB) | -6.34 | -1.73 | +72.7% |
MongoDB, Inc.'s EPS grew from $-6.34 (2016) to $-1.73 (2025).
Chart 6Free Cash Flow — 5 Years
Cellebrite DI Ltd. generated $160M FCF in 2025 (+474% vs 2021). MongoDB, Inc. generated $121M FCF in 2025 (+322% vs 2021).
CLBT vs MDB: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CLBT or MDB a better buy right now?
Cellebrite DI Ltd. (CLBT) offers the better valuation at 43.0x trailing P/E (36.3x forward), making it the more compelling value choice. Analysts rate Cellebrite DI Ltd. (CLBT) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CLBT or MDB?
On forward P/E, Cellebrite DI Ltd. is actually cheaper at 36.3x.
03Which is the better long-term investment — CLBT or MDB?
Over the past 5 years, Cellebrite DI Ltd. (CLBT) delivered a total return of +25.5%, compared to -16.9% for MongoDB, Inc. (MDB). A $10,000 investment in CLBT five years ago would be worth approximately $13K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MDB returned +924.2% versus CLBT's +38.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CLBT or MDB?
By beta (market sensitivity over 5 years), Cellebrite DI Ltd. (CLBT) is the lower-risk stock at 0.83β versus MongoDB, Inc.'s 1.68β — meaning MDB is approximately 103% more volatile than CLBT relative to the S&P 500. On balance sheet safety, MongoDB, Inc. (MDB) carries a lower debt/equity ratio of 1% versus 5% for Cellebrite DI Ltd. — giving it more financial flexibility in a downturn.
05Which has better profit margins — CLBT or MDB?
Cellebrite DI Ltd. (CLBT) is the more profitable company, earning 16.5% net margin versus -6.4% for MongoDB, Inc. — meaning it keeps 16.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CLBT leads at 14.0% versus -10.8% for MDB. At the gross margin level — before operating expenses — CLBT leads at 84.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CLBT or MDB more undervalued right now?
On forward earnings alone, Cellebrite DI Ltd. (CLBT) trades at 36.3x forward P/E versus 68.2x for MongoDB, Inc. — 32.0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLBT: 54.9% to $20.67.
07Which pays a better dividend — CLBT or MDB?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CLBT or MDB better for a retirement portfolio?
For long-horizon retirement investors, Cellebrite DI Ltd. (CLBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.83)). MongoDB, Inc. (MDB) carries a higher beta of 1.68 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CLBT: +38.1%, MDB: +924.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CLBT and MDB?
Both stocks operate in the Technology sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.